[go: up one dir, main page]

EA201990567A1 - Комбинированная терапия с ингибиторами глутаминазы - Google Patents

Комбинированная терапия с ингибиторами глутаминазы

Info

Publication number
EA201990567A1
EA201990567A1 EA201990567A EA201990567A EA201990567A1 EA 201990567 A1 EA201990567 A1 EA 201990567A1 EA 201990567 A EA201990567 A EA 201990567A EA 201990567 A EA201990567 A EA 201990567A EA 201990567 A1 EA201990567 A1 EA 201990567A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combined therapy
glutaminase inhibitors
methods
relates
glutaminase
Prior art date
Application number
EA201990567A
Other languages
English (en)
Inventor
Франческо Парлати
Кит Орфорд
Сэм Х. Уитинг
Original Assignee
Калитера Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Калитера Байосайенсиз, Инк. filed Critical Калитера Байосайенсиз, Инк.
Publication of EA201990567A1 publication Critical patent/EA201990567A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способам лечения рака или миелопролиферативных заболеваний с применением комбинации ингибитора глутаминазы и противоракового средства, выбранного из кабозантиниба, кризотиниба и акситиниба. Изобретение также относится к способам лечения рака или миелопролиферативных заболеваний, которые являются резистентными к одному или нескольким противораковым средствам.
EA201990567A 2016-08-25 2017-08-25 Комбинированная терапия с ингибиторами глутаминазы EA201990567A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379604P 2016-08-25 2016-08-25
PCT/US2017/048581 WO2018039544A1 (en) 2016-08-25 2017-08-25 Combination therapy with glutaminase inhibitors

Publications (1)

Publication Number Publication Date
EA201990567A1 true EA201990567A1 (ru) 2019-08-30

Family

ID=61240223

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990567A EA201990567A1 (ru) 2016-08-25 2017-08-25 Комбинированная терапия с ингибиторами глутаминазы

Country Status (12)

Country Link
US (2) US10278968B2 (ru)
EP (1) EP3503886A4 (ru)
JP (1) JP2019526560A (ru)
KR (1) KR20190040302A (ru)
CN (1) CN110139649A (ru)
AU (1) AU2017315446A1 (ru)
BR (1) BR112019003533A2 (ru)
CA (1) CA3034890A1 (ru)
EA (1) EA201990567A1 (ru)
MX (1) MX2019002108A (ru)
SG (1) SG11201901389XA (ru)
WO (1) WO2018039544A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051041B (zh) 2012-11-16 2018-03-30 卡利泰拉生物科技公司 杂环谷氨酰胺酶抑制剂
AU2015300825B2 (en) 2014-08-07 2019-10-10 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
EP3280415A4 (en) 2015-04-06 2018-12-26 Calithera Biosciences Inc. Treatment of lung cancer with inhibitors of glutaminase
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
SG11201901389XA (en) 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
WO2022177983A1 (en) * 2021-02-19 2022-08-25 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
KR20230001587A (ko) * 2021-06-28 2023-01-05 연세대학교 산학협력단 암의 예방 또는 치료용 약학 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
WO2002076939A2 (en) 2001-02-05 2002-10-03 Exegenics Inc. Cysteine protease inhibitors
EP1747282B1 (en) 2004-04-15 2011-06-08 University of Florida Research Foundation, Inc. Map-2 proteolytic breakdown products as diagnostic biomarkers for neural injury
WO2009104696A1 (ja) 2008-02-19 2009-08-27 株式会社アーネストメディスン 身体機能の回復に有用な経口又は経腸組成物
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
JP2013543009A (ja) 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ， インコーポレイテッド ３−ジュウテロ−ポマリドマイド
CN103030597B (zh) 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
KR20190127971A (ko) 2011-11-21 2019-11-13 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제의 헤테로사이클릭 억제제
BR112015005243A2 (pt) 2012-09-10 2017-07-04 Celgene Corp métodos para o tratamento de câncer de mama localmente avançado
CN105051041B (zh) * 2012-11-16 2018-03-30 卡利泰拉生物科技公司 杂环谷氨酰胺酶抑制剂
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
EP2925318A4 (en) 2012-12-03 2016-07-13 Calithera Biosciences Inc TREATMENT OF CANCER WITH HETEROCYCLIC GLUTAMINASE INHIBITORS
CA2927794A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
BR112016029041A8 (pt) 2014-06-13 2021-07-20 Calithera Biosciences Inc uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
WO2016004418A1 (en) * 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
AU2015300825B2 (en) 2014-08-07 2019-10-10 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
US10517844B2 (en) * 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
WO2016160980A1 (en) 2015-03-30 2016-10-06 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
EP3280415A4 (en) 2015-04-06 2018-12-26 Calithera Biosciences Inc. Treatment of lung cancer with inhibitors of glutaminase
US20180055825A1 (en) 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
SG11201901389XA (en) 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors

Also Published As

Publication number Publication date
BR112019003533A2 (pt) 2019-05-21
US20190275038A1 (en) 2019-09-12
MX2019002108A (es) 2019-07-08
SG11201901389XA (en) 2019-03-28
US10278968B2 (en) 2019-05-07
JP2019526560A (ja) 2019-09-19
KR20190040302A (ko) 2019-04-17
WO2018039544A1 (en) 2018-03-01
EP3503886A1 (en) 2019-07-03
EP3503886A4 (en) 2020-07-22
US20180055843A1 (en) 2018-03-01
CA3034890A1 (en) 2018-03-01
CN110139649A (zh) 2019-08-16
AU2017315446A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX374924B (es) Terapia de combinacion con inhibidores de glutaminasa.
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
MX2018008514A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX393976B (es) Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX381863B (es) Terapias de combinación.
EA201691896A1 (ru) Соединения и способы их применения
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
EA201691846A1 (ru) Композиции и способы лечения рака печени
EA201592012A8 (ru) Применение флагеллина для улучшенной химиотерапии